施保利通联合孟鲁斯特钠治疗儿童变应性鼻炎的临床观察

Clinical Observation of Esberitox Combined with Montelukast Sodium in the Treatment of Children Allergic Rhinitis

目的:观察施保利通联合孟鲁斯特钠治疗儿童变应性鼻炎的临床疗效及安全性。方法:选取变应性鼻炎患儿178例,按随机数字表法分为对照组和观察组,各89例。两组患儿均给予了布地奈德喷雾剂左右鼻孔各喷1次,每喷64μg,bid。对照组患儿在常规治疗基础上口服孟鲁司特钠咀嚼片10 mg,qd。观察组患儿在对照组基础上加服施保利通片0.9 g,tid。两组患儿均治疗3个月。观察两组患儿临床疗效及治疗前后体液免疫[免疫球蛋白(Ig)G、IgA、IgM、IgE]和细胞免疫(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)水平,并比较不良反应发生情况。结果:观察组患儿临床总有效率为91.01%,显著高于对照组的70.79%,差异有统计学意义(P<0.05)。治疗前,两组患儿IgG、IgA、IgM、IgE、CD3^+、CD4^+、CD8^+、CD4^+/CD8^+水平比较,差异无统计学意义(P>0.05);治疗后,两组患儿IgG、IgA、IgE、CD8^+水平显著降低,IgM、CD3^+、CD4^+、CD4^+/CD8^+显著升高,观察组疗效显著优于对照组,差异均有统计学意义(P<0.05)。两组患儿不良反应率比较,差异无统计学意义(P>0.05)。结论:施保利通联合孟鲁斯特钠治疗儿童变应性鼻炎疗效显著,能有效调节患儿免疫功能,且安全性较好。

OBJECTIVE： To observe clinical efficacy and safety of Esberitox combined with montelukast sodium in the treatment of children allergic rhinitis. METHODS： 178 children with allergic rhinitis were selected and divided into control group, and observation group according to random number table, with 89 cases in each group. Both groups were given Budesonide spray, once for left and right onstrils, 64 μg each spoilt, bid. Control group was given Montelukast sodium chewable tablet 10 mg, po, qd, on the basis of routine treatment; Esberitox group was given esberitox tablet 0.9 g, po, tid. Clinical efficacies of 2 groups were observed as well as the levels of humoral immune （IgG, IgA, IgM, IgE） and cellular immune （CD3^＋, CD4^＋, CD8^＋ and CD4^＋/CD8^＋） before and after treatment. The occurrence of ADR was compared. RESULTS： The total effective rate of observation group was 91.01%, which was significantly higher than 70.79% of control group and with statistical significance （P〈0.05）. Before treatment, there was no statistical significance in the levels of IgG, IgA, IgM, IgE, CD3^＋, CD4^＋, CD8^＋ and CD47CD8^＋ be- tween 2 groups （P〉0.05）. After treatment, the levels of IgG, IgA, IgE and CD8^＋ decreased significantly in 2 groups （P〈0.05）, while the levels of IgM, CD3^＋, CD4^＋ and CD4^＋/CD8^＋ increased significantly; the observation group was significantly better than the control group, with statistical significance （P〈0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P〉0.05）. CONCLUSIONS： Esberitox combined with montelukast sodium is effective in the treatment of allergic rhinitis, and can regulate immune function with good safety.